| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_995c71109762882f3cc26e74d8d61acf |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20 |
| filingDate |
2014-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96a35cbc9db8b03f4903861cdaa06c75 |
| publicationDate |
2014-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2014218515-A |
| titleOfInvention |
Polypeptide-vaccine for broad protection against highly virulent meningococcal strains |
| abstract |
Disclosed is a further composition for providing immunity against meningococcal disease and / or meningococcal infection. A small number of defined antigens can provide broad protection against meningococcal infection, and the present invention provides compositions that can induce an antibody response in a subject after administration to the subject. Where the antibody response is related to the highly toxic strain A4, the highly toxic strain ET5, and N.I. bactericidal against two or three of line 3 of meningitidis serogroup B. The composition contains a mixture of no more than 10 purified antigens, rather than consisting of a single antigen, and should not contain an antigen complex such as an outer membrane vesicle or a pending antigen mixture. Five protein antigens are specifically used: (1) “NadA” protein; (2) “741” protein; (3) “936” protein; (4) “953” protein; and (5) “287” protein. . [Selection figure] None |
| priorityDate |
2002-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |